Gudarz Davar, M.D.

Dr. Davar is Executive Vice President, Head of Research and Development at Autobahn Therapeutics.

Dr. Davar is an accomplished neurologist and neuroscientist who brings more than 27 years of corporate and academic leadership in neuroscience research to Autobahn. Before joining Autobahn, he was executive vice president and head of research and development at ACADIA Pharmaceuticals. Prior to ACADIA he was with Eli Lilly where he was vice president, head of global neurology clinical development, the senior leadership role responsible for the global development of all neuroscience and core Lilly biomedicines assets through clinical testing and life of the product. Under his leadership Lilly secured global approvals of Emgality^® for migraine prevention and U.S. approval for the treatment of cluster headache, as well as the U.S. approval of REYVOW^® as a first-in-class, novel, acute treatment for migraine. Prior to Eli Lilly, Gudarz served in senior leadership roles in neurology and clinical development at Allergan, Biogen and Amgen. At Biogen he led the development of PLEGRIDY^® for the treatment of relapsing forms of multiple sclerosis and all development lifecycle activities for AVONEX^®, a leading global multiple sclerosis franchise. Dr. Davar received his medical degree from Dalhousie University in Halifax, Nova Scotia. He completed his neurology residency at University of Michigan Hospitals, Ann Arbor, Michigan and is board certified in neurology.